Efficacy Of Lornoxicam Research Articles

English

English

COMPARATIVE STUDY ON ANTI-INFLAMMATORY SYNERGISTIC ACTIVITY OF LORNOXICAM USING TURMERIC OIL IN TDDS

The present research work was an attempt to develop, evaluate matrix-type transdermal therapeutic system containing lornoxicam with hydrophilic polymer (HPMC E-5) and turmeric oil (leaf extract) by the solvent evaporation technique. The turmeric oil has been used for two reasons, one is to see whether it act as natural penetration enhancer (replacing chemical enhancers) and also to compare the anti-inflammatory synergism between the drug and the oil itself. The anti-inflammatory activity of turmeric oil has been well documented. The physicochemical compatibility of the drug, polymers and oil was studied by infrared spectroscopy. The results suggested no physicochemical incompatibility between them. Five transdermal patch formulations (F1 to F5) consists of HPMC E5 (300 mg fixed) and turmeric oil in the concentrations 3%, 4%, 5%, 6% and 7% respectively were prepared. All formulations carried 10% w/v of Polyethylene glycol as plasticizer in dichloromethane and methanol (4:1) as solvent system. The prepared transdermal patches were evaluated for in vitro release, moisture absorption, moisture loss and mechanical properties. The diffusion studies were performed by using modified Franz diffusion cells. The formulation, F3 showed maximum release 97.56% as compared to patch without any penetration enhancer (58.83%).The synergistic activity has been determined by Carrageenan induced rat paw edema test and the results have confirmed the synergistic activity between the drug and turmeric oil. The developed transdermal patches may increase the efficacy of lornoxicam for the therapy of arthritis and other painful muscular conditions.
 Keywords: Transdermal system, HPMC, Turmeric oil, penetration enhancer, Synergistic activity.

Efficacy of lornoxicam for preemptive analgesia after radical mastectomy surgery

Efficacy of lornoxicam for preemptive analgesia after radical mastectomy surgery

The Comparison of efficacy of lornoxicam and paracetamol for preemptive analgesia in mice

Amac: Preemptif analjezi, agrili uyaridan once bir anal­jezik rejiminin uygulanarak periferik ve santral nosisep­siyonun bloke edilmesi anlamina gelmektedir. Biz bu deneysel calismamizda fareler uzerinde parasetamol ile lornoksikamin preemptif analjezik ozelliklerini karsilastir­mayi amacladik. Gerec ve yontem: Fareler uc gruba ayrildi. Farelerin sag on ayagina formalin enjeksiyonundan once birinci gruba intraperitoneal serum fizyolojik, ikinci gruba lornoksikam ve ucuncu gruba parasetamol enjekte edildi. Islem sonra­si 60 dk boyunca farelerin agri cevabi kaydedildi. Bulgular: Ilk 10 dk\'da lornoksikamin kontrol grubuna gore daha etkin oldugu gorunurken, 11-60.dk ve 0-60. dk dikkate alindiginda parasetamolun lornoksikamdan ve kontrol grubundan daha etkin bir analjezi sagladigi go­rulmustur. Sonuc: Calismamizda akut fazda lornoksikamin parase­tamole gore anlamli fayda saglamasina karsin tonik fazda ve toplam surede parasetamol daha etkin bulunmustur.

Effect of expression of P-glycoprotein in tumor tissue on analgesic efficacy of fentanyl and lornoxicam in patients with cancer pain

Objective To evaluate the effect of the expression of P-glycoprotein (P-gp) in the tumor tissue on the analgesic efficacy of fentanyl and lornoxicam in patients with cancer pain. Methods One hundred advanced cancer patients with pain aged 49-64 yr weighing $$-65 kg were included in this study. The expression of Pgp was positive in the tumor tissue in 50 patients (groups F1 and L1, n = 25 each) and negative in 50 patients (groups F2 and L2, n = 25 each). The patients in 4 groups received 48 h of pstient-controlled intravenous analgesia (PCIA). A loading dose of fentanyl 0.05 mg was administered before PCIA was started in groups F1 and F2 .The PCIA solution contained fentanyl 1 mg and droperidol 5 mg in 100 ml of normal saline in groups Ft and F2, or lomoxicam 64 mg and droperidol 5 mg in 100 ml of normal saline in groups L1 and L2. The PCA pump was set to deliver a background infusion of 2 ml/h and a bolus dose of 0.5 ml at 15 min lockout interval. Pain was assessed with VAS scores (0 = no pain, 10 = worst pain), and VAS score was maintained at ≤3 during PCIA. Flurbiprofen 50 mg was injected intravenously when VAS score≥4 and the consumption of flurbiprofen was recorded. The consumption of fentanyl and lornoxicam during PCIA was recorded. Blood samples from the internal jugular vein were taken at the beginning of PCIA (T0), and at 4, 12, 24, 48 h of PCIA (T1-4) for determination of blood fentanyl and lornoxicam concentrations. Results Flurbiprofen was not used in groups F2, L1 and L2. The consumption of flurbiprofen was ( 184 ± 41 ) mg in group F1 . There was no significant difference in the consumption of fentanyl during PCIA between groups F1 and F2 ( P ＞ 0.05). Blood fentanyl concentrations were not detected at all the time points in groups F1 and F2 . The VAS score during PCIA ≤ 3 in groups L1 and L2, and there was no significant difference in blood concentrations of lornoxicam at each time point and the consumption of lornoxicam during PCIA between groups L1 and L2 ( P ＞ 0.05). Conclusion Positive P-gp expression in the tunor tissue can decrease the analgesic efficacy of fentanyl, but exerts no effect on the analgesic efficacy of lornoxicam in patients with cancer pain. Key words: Glycoproteins; Fentanyl; Cyclooxygenase inhibitors; Neoplasms; Analgesia

Efficacy of Levobupivacaine Wound??Infiltration With and Without??Intravenous Lornoxicam for??Post-Varicocoele Analgesia

The oxicam NSAID lornoxicam is a potent analgesic with excellent anti-inflammatory properties in a range of painful and/or inflammatory conditions, including postoperative pain. Levobupivacaine, the S-(-)-isomer of bupivacaine, is a long-acting local anaesthetic that can be infiltrated into wounds for management of postoperative pain. We assessed the analgesic efficacy of lornoxicam when administered as an adjuvant to levobupivacaine wound infiltration after varicocoele operation. Sixty patients who underwent varicocoele surgery were randomly assigned to three different treatment groups. Before skin closure, patients received the following treatments: group I (n=20) patients received normal saline 20 mL wound infiltration and intravenous lornoxicam (Xefo, Nycomed Pharma AS, Roskilde, Denmark) 2 mL (8 mg); group II (n=20) patients received 0.25% levobupivacaine (Chirocaine, Abbott Scandinavia AB, Solna, Sweden) 10mL with normal saline 10 mL wound infiltration and intravenous normal saline 2 mL; group III (n=20) patients received 0.25% levobupivacaine 10 mL with normal saline 10 mL wound infiltration and intravenous lornoxicam 2 mL (8 mg). Pain scores and total pethidine (meperidine) consumption were measured at 1, 2, 4, 6, 12 and 24 hours postoperatively. Time to first analgesic requirement and patient satisfaction were also compared post-surgery. Pain scores during the first 6 hours postoperatively were significantly lower in group III than in group I and group II (p<0.01). Total pethidine consumption was significantly lower in group III (34.0+/-28.0 mg) than in group I (74.0+/-25 mg) and group II (76.0+/-29 mg) [p<0.01]. Time to first analgesic was also significantly longer in group III (14.8+/-8.4 hours) than in group I (6.2+/-5.2 hours) and group II (5.8+/-7.1 hours) [p<0.01]. The incidence of postoperative nausea and vomiting was significantly lower in group III than in group I and group II (p<0.05). More patients in group III described their analgesia as good or excellent than in group I or group II (p<0.01). In this study, levobupivacaine wound infiltration with adjuvant intravenous lornoxicam administration was associated with better postoperative analgesia during the early postoperative hours after varicocoele surgery than that induced by lornoxicam alone or levobupivacaine wound infiltration alone.

Comparison of lornoxicam versus tramadol analgesia for transrectal prostate biopsy: a randomized prospective study

We compared the efficacy of lornoxicam and tramadol to provide analgesia and comfort during transrectal ultrasound-guided biopsy of the prostate (TRUSP) as a noninvasive method. A total of 62 men undergoing TRUSP were enrolled in this study. Patients were randomized to three groups. Group 1 (n = 21) received 8 mg of lornoxicam, group 2 (n = 21) received 100 mg of tramadol, and group 3 (n = 20) received saline as a control. The drugs were given intramuscularly half an hour prior to the procedure. All patients were asked to indicate the level of pain experienced after the procedure by visual analog score (VAS), and the patient's comfort level was scored by a comfort score. Additionally, the patients were asked if they were willing to undergo a future TRUSP. The data obtained revealed that both experimental groups receiving lornoxicam and tramadol had lower VAS scores compared to the control group (3.4 and 2.4 vs. 6.4, respectively; P < 0.0001). There were also significant differences in VAS scores between group 1 and group 2 (P = 0.027). There was a significant difference in the comfort score between the drug groups and control (P > 0.0001) and between the lornoxicam and tramadol group (P < 0.05). Pain and discomfort were least in the tramadol group. The percentage of patients who would not consent to future TRUSP was lower in the drug groups compared to control (P < 0.0001). But there were not any differences between the drug groups. The use of lornoxicam or tramadol for pain relief in TRUSP is a practical, effective and comfortable method compared to the results of the control group. In addition, tramadol was found to be more effective than lornoxicam.

Intravenous Administration of Lornoxicam, a New NSAID, and Pethidine for Postoperative Pain

In order to determine the efficacy of lornoxicam in postoperative pain, an observer-blind, placebo-controlled, multiple-dose study was conducted. 80 patients (26 female, 54 male, aged 24 to 61 years) with moderate to severe pain after laminectomy were randomised to receive lornoxicam 4 or 8mg intravenously, pethidine 50mg intravenously or isotonic distilled water (placebo) at their first request for analgesia. Efficacy was determined by the time between the first dose and the first request for remedication, pain intensity differences from baseline (PID) measured by verbal rating scales, the total number of doses required over 24 hours, and patients’ overall impression of efficacy. The median time to remedication was 35 minutes for placebo, 38 minutes for lornoxicam 4mg, 100 minutes for lornoxicam 8mg and 75 minutes for pethidine. Mean PID values were −0.5 for placebo, −0.6 and −0.8 for lornoxicam 4 and 8mg, respectively, and −0.7 for pethidine. Patients receiving lornoxicam 8mg required a mean of 2.6 doses over 24 hours, whilst other groups required 3 doses. There was a consistent trend towards superior efficacy with lornoxicam 8mg and pethidine 50mg, followed by lornoxicam 4mg, then placebo; this was reflected in patients’ overall ratings of ‘good’ for lornoxicam 8mg and pethidine, ‘good to fair’ for lornoxicam 4mg, and ‘fair’ for placebo. Two patients in the lornoxicam 8mg group and 4 in the pethidine group reported adverse events, mostly mild to moderate nausea. One patient in the pethidine group discontinued treatment because of bradycardia. In summary, lornoxicam 8mg intravenously was as effective as pethidine 50mg intravenously in relieving moderate to severe postlaminectomy pain, and had few adverse events.